
Ophthalmology news, research, and analysis. Official @SpringerNature channel.
London, UK
Joined September 2023
- Tweets501
- Following50
- Followers127
- Likes17
👁️ New models of care are emerging…Allied health professional–led keratoconus services:
✅ Improve efficiency
❓ Risk losing specialist inputWhich side are you on?💬 Join the debate
🔗 doi.org/10.1038/s41433-026-0…
#Ophthalmology
1
31
👁️ Retinitis pigmentosa isn’t one story.
This study looks at visual acuity across 4 rod phototransduction genes.
Which factor matters most here:
🧬 Gene type
⏳ Disease stage
👤 Patient variability
Drop your pick 👇
🔗 doi.org/10.1038/s41433-026-0…
1
32
🥽 Can virtual reality improve understanding of visual impairment?
This study explores how VR shapes parents’ perspectives.
On a scale of 1–10, how impactful could this be? 👇
🔗 doi.org/10.1038/s41433-026-0…
#Ophthalmology
24
👁️ Barriers to eye exams:
Cost, access, awareness… and ______?
This study explores patient experience + what prevents people attending.
Add the missing barrier 👇
🔗 doi.org/10.1038/s41433-026-0…
#Ophthalmology
15
👁️ Myopia + glaucoma: what needs the most focus?Rank your priority (1–3):
🔍 Diagnostics
📈 Monitoring progression
💊 Treatment strategies
See how experts prioritise 👇
🔗 doi.org/10.1038/s41433-026-0…
#Glaucoma #Ophthalmology
21
👁️ Fellow eye effect—real or rare?
Does treating one eye change the other?
One word, how does it affect your practice?👇
🔗 doi.org/10.1038/s41433-026-0…
19
💉 Myth or fact?
“Intravitreal drug efficacy is mainly about dose, not pharmacokinetics.”
A new primer unpacks the key principles shaping real-world outcomes in ophthalmology.
👇 Myth or fact—what’s your take?
🔗 doi.org/10.1038/s41433-026-0…
#Ophthalmology
14
🤖📣 “Large language models in medical advertising will ______.”
Disrupt practice? Improve access? Raise concerns? This paper explores the emerging influence of AI on medical decision-making.
💬 Finish the sentence below
🔗 doi.org/10.1038/s41433-026-0…
#AIinMedicine
13
🏥 Community eye clinics: game changer or growing pain? New study explores patient & staff experiences in community-based diagnostics for chronic eye conditions.
👍Improved access
👎 Service challenges
Which stands out to you? 💬
🔗 doi.org/10.1038/s41433-026-0…
#Ophthalmology
14
👓 24-month results are in for a new myopia control lens in children…
But first—quick test:
📊 Do you think it significantly slowed progression?
Reply with YES / NO before checking 👇
🔗 doi.org/10.1038/s41433-026-0…
#Myopia #Ophthalmology
18
🧠👁️ Can AI transform AMD care before symptoms even begin?
I-SCREEN introduces a scalable system for community screening + progression prediction—bringing shared retinal care closer to reality.
Are we ready for this shift? 💬
🔗 doi.org/10.1038/s41433-026-0…
#AIinHealthcare #AMD
1
30
👁️ New data from the Phase 3 PULSAR trial (Week 96) High-dose aflibercept (8 mg) for nAMD shows promising efficacy & safety.
📊 What matters most in long-term AMD treatment? doi.org/10.1038/s41433-026-0…
0%Durability
0%Visual acuity gains
0%Safety Profile
0%Real-world feasibility
0 votes • Final results 31
🌙 Autosomal dominant Riggs-type congenital stationary night blindness with fundus sheen and retinal atrophy due to a novel GNAT1 p.Gln200Arg variant. link.springer.com/article/10…
2
17
👁️⚠️Retinal vein occlusion may be the clue—not the cause—pointing to undiagnosed glaucoma hiding in plain sight. link.springer.com/article/10…
1
33
👁️🌍Looking beyond the macula to map what “normal” really looks like across the choroid.
link.springer.com/article/10…
1
29
🧬👁️Systemic immune control with benefits beyond joints and skin—evidence points to fewer uveitis flares. link.springer.com/article/10…
9
A new journal, uncovered 👁️🧠
NeuroRetina emerges with its inaugural article and editorial mapping the interface of neuroscience and retinal research with clarity and intent. The beginning of something worth following closely:
link.springer.com/article/10… #NeuroRetina
22
👁️🤖When eye imaging meets machine learning, what can we really predict?link.springer.com/article/10…
21
🧠👓 Do contact lenses have to correct vision to influence eye growth?nature.com/articles/s41433-0…
20
As biosimilars mature, an uncomfortable question comes into focus: are phase III retinal trials still necessary? Rethinking phase III trials in retinal biosimilars: Do we still need them? nature.com/articles/s41433-0…
1
34